key: cord-0979555-phby6ouv
authors: Chan, Winglam; He, Betsy; Wang, Xiong; He, Ming-Liang
title: Pandemic COVID-19: current status and challenges of antiviral therapies
date: 2020-07-07
journal: Genes Dis
DOI: 10.1016/j.gendis.2020.07.001
sha: fabd054d3637c4c87ecc506058d771ae30274560
doc_id: 979555
cord_uid: phby6ouv

Abstract The pandemic COVID-19, caused by a new coronavirus SARS-CoV-2 infection, has infected over 6 million individuals and caused more than 364,000 death worldwide. Currently, there is no specific drug to treating this disease. Here we summarized the mechanisms of antiviral therapies and the clinic findings from different countries. Antiviral chemotherapies have been conducted by in multiple cohorts in different counties. Although FDA has fast approved remdesivir for treating COVID-19, it only speeds up recovery from COVID-19 with mildly reduced mortality. The chloroquine was suggested a potential drug against SARS-CoV-2 infection due to its in vitro antiviral effects, it is imperative high-quality data from worldwide clinical trials are necessitated for an approved therapy. In terms of hydroxychloroquine (HCQ) therapy, although WHO has stopped all the clinic trials due to its strong side-effects in COVID patients, large scale clinical trials with a long-term outcome follow-up may warrant HCQ and azithromycin combination in combating the virus. Convalescent plasma (CP) therapy suggested its safety use in SARS-CoV-2 infection; but both CP immunotherapy and NK cellular therapy must be manufactured and utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin. Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or ex vivo human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating highly effective therapies.

After outbreak of severe acute respiratory syndrome (SARS) December 2019. It is found that the causative agent of this pandemic was caused by a novel coronavirus SARS-CoV-2 (CSG of the International, 2020). This novel infectious disease is encountered by over 210 countries and territories around the world (worldometers.info, 2020), leading to a newly emerging global crisis.

Up till now, SARS-CoV-2 has spread internationally with over 9.1 million patients diagnosed and over 471,000 deaths worldwide (worldometers.info, 2020) by June 22, 2020. In the Western Pacific Region, China is the country hit most severely with a total confirmed case of 83,396 (WHO, 2020) . Whereas the USA, UK, Spain and Italy have become the most unfortunate countries exposed to this overwhelming disease in the region of the Americas and the European region respectively. The US has taken over 2.37 million confirmed cases with over 120,000 deaths (CDC, 2020), while Italy had reported the percentage of patients in intensive care who are actively infected was consistently between 9% and 11% from March 1 up until Match 11 (Remuzzi, A. , & Remuzzi, G., 2020).

At a glance, the spread of COVID-19 and its overwhelming virulence have turned into an unstoppable crisis which has already reached the required epidemiological standard for it to be declared a pandemic, with infected cases exceeding 100,000 in 100 countries in just three months and only 12 days to reach the next 100,000 (Callaway. E, 2020) .

It is of paramount importance to implement a series of medical interventions to overcome the challenges brought by COVID-19 and govern this grievous plague efficiently. While awaiting the development of vaccination, prompt and precise medical treatment plays a crucial role in this demanding situation. However, there are no specific therapies approved officially by the U.S. Food and Drug Administration (FDA) to treat COVID-19 (Tim, Jennifer, & Tony, 2020) . Consequently, identifying effective therapies to combat the disease is a pressing need. Either antiviral treatment or cellular therapy may lead to the complete or partial success of a cure for the patients, depending on its level of effectiveness. Thus, the effectiveness of treatment is critically responsible for the overall improvement of this pandemic disease and deserves to be studied extensively to enhance the clinical intervention.

Based on the mortality rate of COVID-19 is about 6% globally, learning more about the effectiveness and differences between drug therapies help to contribute to a more successful treatment. This literature review will summarise and discuss different types of therapies, including compassionate uses of antiviral drugs (which are now undergoing their clinical trials owing to a lack of clinical experience) and on in-vitro activity against this novel virus. Besides, we will also explore cellular and immunotherapy to highlight their therapeutic potentials. This review would give an insight of feasible development of potent medications and provide a framework for possible intervention strategies in a foreseeable future.

Fig. 1 . Basic structure of coronaviruses. (Seah, Su, & Lingam, 2020) Structure of SARS-CoV-2 SARS-CoV-2 belongs to Betacoronavirus, the same genus as contagious Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) in coronavirus family. Their genome is composed of a positive-sense single-stranded RNA (+ssRNA). SARS-CoV-2 comprises of four structural proteins which aid in assembling and infection --the transmembrane spike glycoprotein (S), membrane protein (M), envelop protein (E) and nucleocapsid protein (N) (Tortorici, & Veesler, 2019) . Among these proteins, viral attachment and entry into host cells are mediated by the S protein. It is surfaceexposed and can be cleaved by host proteases into S1 and S2 subunits (Yuan et al., 2017) . The cleavage allows initiation of the membrane fusion via a large scale irreversible conformational changes (Walls et al., 2017; Belouzard, Chu, & Whittaker, 2009 ). The S1 subunit consists of the receptor-binding domain(s) (RBD) that can undergo hinge-like conformational movements, leading to a transient hidden or exposure of receptor binding determinants and thus mediates the engagement of a host receptor (Wrapp et al., 2020) . Therefore, it has been suggested that the critical RBD(s) is responsible for the determination of cell tropism, host range and zoonotic transmission of coronaviruses (Graham, & Baric, 2010) . Subsequently, the S1 subunit stabilizes the profusion conformation of the membrane-bound S2 subunit which contains the fusion machinery (Gui et al., 2017; Walls et al., 2019) . Hence, the intricate processes of host receptor binding and proteolytic cleavage of the S protein are essetial for the viral entry into susceptible targets. The comprehension of structure and function of the S protein help to formulate a timely strategy for a specific drug such as monoclonal antibody drugs, as well as the development of vaccines in a foreseeable future.

The life cycle of SARS-C0V-2 Upon entering the host cell with the aid of S protein, SARS-CoV-2 releases its RNA genome into the cytoplasm, it translates into structural proteins and two polyproteins, pp1a and pp1ab, they are then split into small products via viral proteinase cleavage (Perlman, & Netland, 2009 ). Afterwards, the viral genome begins to replicate, the positive-strand genome undergoes discontinuous transcription to synthesize the subgeneric negative-strand templates, templates for mRNA synthesis are thus generated, while the full-length negative-strand template is served as a genomic RNA template. Followed by the formation of viral nucleocapsids via a combination of genomic RNA and N protein in the cytoplasm, as well as the insertion of the newly formed envelope glycoproteins into the membrane of the endoplasmic reticulum (ER) or Golgi, the viral particles are then budded into the lumen of ER-Golgi intermediate compartment (ERGIC). It is then followed by the release of virions through exocytosis. Finally, the vesicles containing virions fuse with the plasma membrane to infect other host cells (Stertz et al, 2007) . It must be pointed out that the above process is a replication basis of SARS-CoV, the exact pathophysiological mechanisms underlying the emergence of SARS-CoV-2 still awaits exploration. SARS-CoV-2 mutations impact the viral pathogenicity Noteworthily, the pathogenicity of SARS-CoV-2 are found to be influenced by patient-derived mutations. It is identified that 19 of the 33 mutations are novel in the collection of 11 viral isolates, in which 6 mutations are localized in spike protein . This indicates that the polymorphism of SARS-CoV-2 is much more than expected and the site of mutation may highly affect the viral pathogenesis. Strikingly, two viral isolates at 24 hours post-infection (p.i.) have reported a nearly 270-fold difference in viral load. In addition, an unexpected tri-nucleotide mutation was observed in one viral isolate, which resulted in viral positivity for a sustainable period of 45 days . Further studies should be directed towards the mutational impact of tri-nucleotide on the viral pathogenicity.

Ahough this non-peer-reviewed journal cannot be served as a clinical guideline, it has provided a significant insight for therapies development by taking the impact of the accumulating mutations into account to prevent potential pitfalls.

The similarity between SARS-CoV and MERS-CoV SARS-CoV-2 shares more than 85% of its identity with SARS-CoV (Wu et al., 2020) . What is more, a greater similarity of (>90%) sequence identity is observed in the RNA-dependent RNA poymerase (RdRp) between them. This poses a suggestion of RdRp inhibitors being the candidate drug for COVID-19 (Liu, Morse, Lalonde, & Xu, 2020). Revealingly, the same receptor of SARS-CoV, angiotensin-converting enzyme 2 (ACE2) is also used by SARS-CoV-2 (Hoffmann et al., 2020), which is highly expressed in a small subset of cells in the lung called type 2 alveolar cells . Interestingly, SARS-CoV-2 conserves 8 binding-residues of 14 these amino acids in SARS-CoV, which are responsible for direct interaction with ACE2 (Fehr, & Perlman, 2015) . To note, there is a nearly 10-to 20-fold higher affinity in the SARS-CoV-2 S protein binding to ACE2 than that of SARS-CoV, implying an increased ease in spreading between humans (Wrapp et al., 2020) . This indicates that SARS-CoV-2 is highly similar to the receptor-binding domain in S protein of SARS-CoV.

In contrast, SARS-CoV-2 is less related to MERS-CoV; only 50% of its genetic sequence identity is shared with SARS-CoV-2 . Moreover, the primary receptor of MERS-CoV present in the lower respiratory tract, dipeptidyl peptidase 4 (DPP4), is not exploited by SARS-CoV-2 . Nonetheless, MERS-CoV shares highly similar pathological characteristics with COVID-19, including viral cytopathic-like changes of giant cells multinucleation along with atypical enlarged pneumocytes in the intra-alveolar spaces , suggesting to some extent the epidemiological characteristics of SARS-CoV-2 is similar to that of MERS-CoV. General principles of the same Coronaviridae family may govern its biological activities.

Besides, these three CoVs all show a similar innate immune response. A highly proinflammatory condition was observed in patients with SARS-CoV-2 infection who needed intensive care unit (ICU). They showed increased plasma levels of many innate cytokines . Both SARS and MERS also have this noticeable growth, signifying a potential similar cytokine storm-mediated disease severity (Mahallawi, Khabour, Zhang, Makhdoum, & Suliman, 2018; Wong et al., 2004) . Altogether, identifying the similarity of pathological and immunological characteristics with SARS-CoV and MERS-CoV could facilitate our knowledge of pathophysiological mechanisms underlying the emergence of SARS-CoV-2. The genetics similarity with SARS-CoV also aids in the interpretation of the resulting inflammatory response that may trigger the onset of severe pneumonia (Fehr, & Perlman, 2015) . By comprehending these similarities with the precedential SARS-CoV and MERS-CoV, it is believed that it increases the likelihood for the physicians to design efficient therapeutic measures for the COVID-19 patients and reduce fatality.

Cytokine storm While the pathogenesis of SARS-CoV-2 is still elusive and there is uncertainty with respect to its mechanism of viral transmission, the similar mechanisms of other pathogenic CoV provide useful information to enhance our recognition of COVID-19. Since SARS-CoV-2 requires the same receptor as SARS-CoV (ACE2) for viral entry, aerosol and fomites transmission of SARS-CoV-2 is plausible (van Doremalen, et al, 2020). Upon entry into alveolar epithelial cells via exploitation of ACE2, the virus replicates rapidly by infecting pneumocytes and macrophages (Shieh et al, 2005) . This triggers the antigen presentation in CoV infection, leading to a strong cellular and humoral immune response. Ultimately, the cytokine storm and pulmonary tissue damage Besides, as mentioned above, this deadly cytokine storm-mediated condition is also observed in SARS and MERS (Mahallawi et al., 2018; Wong et al., 2004 ). An increased level of IL-6, IFN-α, and CCL5, CXCL8, CXCL10 in serum was observed in patients with severe MERS-CoV infection in contrast to those with the mild-moderate disease (Min et al, 2016) . Also, the dead has a distinctively higher level of IL-18, IP-10, MG, and MCP1 than in those of the survivors of severe SARS-CoV infected patients (Huang et al, 2005) . Likewise, the immune response of some patients against the SARS-CoV-2 causes an elevation of IL-6 (Huang et al., 2020). The data have strongly emphasized that these three CoVs share the common immunopathological events which provoke a vigorous attack by the immune system to the host body, giving rise to ARDS and MOF. Furthermore, a model of ex-vivo human lung tissue revealed that SARS-CoV-2 generated 3.2 folds higher amounts of infectious viral particles than that of SARS-CoV within 48h p.i.. Surprisingly, despite the more efficient replication, SARS-CoV-2 did not trigger significant levels of interferons in infected human lung tissues (Chu et al., 2020) . The preliminary data have explained the high person-to-person transmissibility of this novel virus. Moreover, its low degree of innate immune activation accounts for the false-negative in patients who have mild or even asymptomatic infections, which promotes the COVID-19's spread by "stealth transmission". In short, SARS-CoV-2 acts as a ninja which is not easily detected while maintaining its potency. If the mechanism that renders these viral characteristics of high transmissibility and symptomatic infection can be elucidated in the future researches, more precise treatment strategies and infection controls can be developed for COVID-19 patients, especially for those who immunocompromised.

Although advancement in drug improvement occurs frequently, de novo drug development is costly and timely. In this moment of global emergency, a drug to cure the ailment is needed as soon as possible. Inventing a new drug from scratch would cost too much time, which in this case, cost too many lives. Instead, repurposing existing drugs for a new disease is always the preferred first step since animal and safety trials are not required which could shorten the time to roll out the drug and reduce its cost. A possible way for drug exploration with considerable interest is to test if the (Agostini et al., 2018) . The mechanism of naturally developed resistance mutation still remains unknown. Because of this, we cannot rule out the possibility of remdesivir resistance, since the same study had shown that remdesivir was more sensitive towards the mutated MHV that lacked proofreading capability (Agostini et al., 2018) . This implies there is a likelihood for either a mutation that enhances proofreading or strengthens replication fidelity that ends up in the emergence of drug resistance (Kirchdoerfer, & Ward, 2019) . Further studies should be conducted to understand such resistance mutations for improving the effectiveness of remdesivir.

Nonetheless, remdesivir has been widely applied to over a hundred patients infected with SARS-CoV-2 in the US, Europe, and Japan through Expanded Access or Compassionate Use programs (Bender, 2020) . Presently, evaluation of remdesivir efficacy in patients have been conducted by randomized, controlled, and double-blind clinical trials. More recently, remdesivir showed clinical improvement in 36 of 53 (68%) patients with COVID-19 in a preliminary report (Grein et al., 2020) . The mortality was 13% over a median follow-up of 18 days, compared to the 28-day mortality of another randomised, controlled trial of lopinavir-ritonavir in patients, which was 22% . Although this trial is conducted in a small size of the cohort and there is a lack of viral load data to confirm the antiviral effects of the drug, the mortality and clinical improvement shown in this cohort are optimistic. In May, report from big size of cohort revealed improved therapeutic effects with speed up recovery from COVID-19 although it only mildly reduced mortality. Therefore, FDA has fast approved this drug for treating COVID-19.

In vitro data have shown its influential antiviral activity against a clinical isolate of SARS-CoV-2. Similar to remdesivir, chloroquine has a high selection index (SI) and inhibits SARS-CoV-2 at a low micromolar concentration (EC50 = 1.13 μM; CC50 > 100 μM, SI > 88.50), suggesting a decent chance of it becoming a potential treatment candidate .

As an antimalarial drug, chloroquine has been used for over 70 years. It is chosen from the tens of thousands of existing drugs because of the reported antiviral effects in patients with SARS-CoV (Vincent et al, 2005) . Chloroquine had become less relevant as the SARS outbreak died and there were no new cases of CoVs until now. Recognising that the current SARS-CoV-2 is similar to SARS-CoV genetically, chloroquine was considered again as a therapeutic measure for the novel pandemic.

Principally, several antiviral functions are involved in the use of chloroquine. A well-known function is that chloroquine can act as an inhibitor to the endosomal acidification to block CoV replication. A previous study declared as the viral entry is mediated by fusion competent SARS-CoV S protein in a pH-dependent manner, they require endosomal acidification for entry (Simmons et al, 2004 ). The endosomal acid proteases are used to cleave the S protein, whereby activating fusion Taken together, the multiple mechanisms of chloroquine can potentially achieve a promising therapeutic effect against SARS-CoV-2 infection. The reduction of SARS-CoV infectivity and cell spread was attained in the presence of 1-10 μM chloroquine, which is clinically achievable in the plasma of malaria-infected patients (Ducharme, & Farinotti, 1996) . The EC90 value of this drug against the SARS-CoV-2 in Vero E6 cells was 6.90 μM, which is the plasma concentration achievable for rheumatoid arthritis treatment .

These data support that chloroquine can interfere with SARS-CoV-2 in a feasible and rather effective dosage.

Due to the numerous pros as mentioned above, preliminary trials of chloroquine have been conducted in many countries. 70% of COVID-19 patients were con- ). Yet, currently, there is no published scientific journal reporting the precise data from the clinical trials, which poses a difficulty in interpreting results. Likewise, although the inhibitory effect of chloroquine was observed in the pneumonia patients with COVID-19, no specific data were available for result interpretation, even though a significant effect in terms of clinical outcome and viral clearance has been shown when compared to controls groups (Gao, Tian, & Yang, 2020) . In light of the foregoing, it is imperative high-quality data from worldwide clinical trials are necessitated for chloroquine to become an approved therapy. Given the fact that chloroquine exerts remarkable inhibitory antiviral effects on the susceptible cells, it is highly recommended to be considered as the treatment candidate for both prophylactic and therapeutic use.

Hydroxychloroquine Hydroxychloroquine (HCQ) was also suggested as candidate drug. It is a derivative of CQ by introducing a hydroxyl group into CQ. Hence it is not surprising that it shares (Savarino et al., 2003) almost the same pharmacological properties as CQ (Browning, 2014 . This drug is only approved for human use by prescription for the parasitic treatment, and for preventing heartworm disease in animals (Campbell, 1989) . Since the drug called Heartgard containing ivermectin is available in veterinary clinics (Campbell, 1989) , Momekov have raised a concern about that a trend of self-medication for COVID-19 may be evoked ( Side effects raised by these drugs such as QT prolongation should also be monitored and cautioned.

Further investigations of the efficacy of antiviral drugs in wide clinical applications should be undertaken to combat this deadly pandemic as soon as possible.

The therapeutic value is highlighted in immunotherapy as like as antiviral therapy. While awaiting the approved specific antiviral agents for COVID-19 via clinical trials, convalescent plasma (CP) therapy is also approached as a potential candidate. It is a classic adaptive immunotherapy which provides the plasma from recovered patients with a high neutralising antibody titer to a susceptible person. Upon circulation of the blood, the antibodies reach the target tissue and confer an- (Halstead, 2015) . This was observed in SARS-CoV infection in vitro (Wang et al., 2014) . Nonetheless, ADE may be unlikely to happen in COVID-19 as the proposed use of CP would rely on preparations with high titers of neutralizing antibody and timely transfusion (Duan et al., 2020) . Furthermore, given the advanced blood banking techniques, the risks of the above contraindications and inadvertently TTI can be minimized via screening the suspected pathogens and matching the blood type of donors and recipients.

Overall, given the experience and current preliminary data on the use of CP therapy suggest its safety use in SARS-CoV-2 infection (worldometers.info, 2020). This treatment would be a boon for critically ill patients to improve their survival rate. It is also beneficial if administered at an early stage of the disease, more randomized clinical studies should be conducted for a risk-benefit assessment in individual variables. Moreover, SARS-CoV-2 specific hyperimmune serum such as Takeda's TAK-888 (Takeda, 2020) and Kamada's anti-COVID-19 IgG (Weinreb, 2020) are now developing, these have undoubtedly provided additional options for COVID-19 rescue.

Natural killer (NK) cells are innate cytotoxic lymphocytes essential for host-rejection of both tumours and virus-infected cells. Therefore, NK cell therapy is a common therapeutic approach for solid tumours and haematological malignancies, whereas recently NK cells are evolutionarily designed to detect and eliminate virus-infected cells, which can be developed into a practical treatment for COVID-19. It is presumed that NK cell lyses antibody-coated virus-infected cells via ADCC, a key effector function (Hammer, Rückert, & Romagnano, 2018) .

Normally stimulation and effector function of NK cell relies on the integration of signals derived from activating and inhibitory receptors. The surface of normal cells has expressed major histocompatibility complex (MHC) class I molecules to act as ligands for inhibitory receptors and conduce to the self-tolerance of NK cells. Whereas to evade T-cell recognition, viruses reduce ex-pression of the MHC I molecules and result in a low inhibitory signal of NK cells. Plus, DNA damage response (DDR) activated by the virus increases cellular stress. Altogether these shift the balance of the signal towards NK cell activation, followed by stimulation of NK cells to remove virusinfected cells directly via ADCC or indirectly through secretion of pro-inflammatory cytokines at the times before replicating virion assembly and spreading of virus (Lanier, 2008) . Apart from the positive signaling, this defense mechanism also requires a cell to cell contact to initiate. Therefore, it is necessary to form a lytic synapse between the target cells and NK cells.

The actin cytoskeleton is reorganized followed by polarization of microtubule organizing centre and secretory lysosome toward the lytic synapse. After docking to the plasma membrane of NK cells at the synapse, the secretory lysosome, eventually, is fused with the target cell plasma membrane to liberate its cytotoxic granules (Paul, & Lal, 2017) . Perforin, a membrane pore-forming molecule which can permeabilise the cells (Tay, & Welsh, 1997) . This allows the entry of a serine protease, granzyme, into the target cells and activate caspase molecules to induce apoptosis of target cells (Orange, & Biron, 1996) and influenza virus (Monteiro, Harvey, & Trinchieri, 1998) ; however, it is not demonstrated in lymphocytic choriomeningitis virus (LCMV) (Orange, & Biron, 1996) . The above infections have shown the NK cell response is dependent upon the endogenous IL-12, conclusively suggesting that the IFN-γ production by NK cells is an outcome of IL-12 during viral in-fection. It would be reasonable to consider NK cell therapy for treating COVID-19, particularly for those who are unrelieved by antiviral medicine. On these grounds, to clarify the immune-mediated component of NK cells of COVID-19, efforts to develop an animal model would be appreciated. Be alert, cytokine storm induced by the exaggerated production of IFN-γ may be involved in the immunopathological damage in patients with COVID-19. Therefore, NK cell therapy may not be suitable for those patients who are suffered from cytokine storm syndrome, especially the critical illness individuals as aforementioned in this review . The therapeutic value of this therapy, alternatively, may be reflected in immunocompromised patients with COVID-19. In view of this, a thorough risk-benefit assessment must be committed to investigating the potential immune impact, particularly dose-response relationship should be taken into account during the clinical trial.

Unlike the antiviral drugs, NK cell therapy is fully dependent on harnessing the human immune system to fight the virus. Since NK cells can be differentiated from induced pluripotent stem cells (iPSCs) and gained from umbilical cord blood, they are a promising source of allogeneic NK cells and are potential to be true off-the-shelf cellular therapies, whereby providing NK cells with a patient-specific basis. Allogeneic induced NK therapy does not require a treatment involving patient-specific cells that spend weeks to synthesize, and it can be applied repeatedly, with the potential to improve clinical benefit based on optimisation of dose and schedule. In addition, NK cells are capable in recognising various infected cells without the reliance of the presentation of a single antigen, it is superior to T-cell based therapy as it omits some of the resistance mechanisms (Amorosi, 2019) . Most importantly, a clinical and manufacturing collaboration is designed to extend the therapeutic use of CYNK-001 to COVID-19 (GlobeNewswire, 2020). If this allogeneic, off-the-shelf, placental-derived NK therapy shows a satisfactory result, it is feasibly to become a potential novel treatment for COVID-19.

Lastly, for both CP immunotherapy and NK cellular therapy, CP/NK must be manufactured and be utilized according to scrupulous ethical and controlled conditions to guarantee a possible role of these products of human origin.

The novel COVID-19 situation has escalated into an unprecedented worldwide crisis in the last few months. The scientists and physicians continue to actively monitor the developments, particularly paying attention to the health and rescue of sufferers and the community at large. With the concerted efforts and commitment to researches, many therapeutic regimens have been explored and advocated in the absence of definitive management protocols. Some therapies may be devel- an urgent unmet that need to determine the optimal treatment including specific antiviral therapy, modulating rationale of the immune system, as well as the capability of supporting failed organ systems. However, it is a pity that some of the studies have not been further analysed since they lack scientific rationale, insufficient provision of information regarding active ingredients and the applicability to mainstream medical practice is finite (Lythgoe, & Middleton, 2020) . These indeed pose an obstacle towards a successful intervention for COVID-19, if no improvement for these limitations is done, the postponed development of efficient therapy, in particular, concerning the area of investigations on unmet medical need and life-threatening diseases, will lead to a delay in patients' access to treatment in hospitals. Hence it is essential to overcome the challenges to achieve satisfactory and undisrupted access to treatment in hospitals. (Lythgoe, & Middleton, 2020) . The upcoming preliminary data may not be sufficient to warrant CP therapy as an official therapy but to provide supportive evidence in proving its competence and feasibility. It is estimated that there is still a distance for plasma-based therapy to reach the standard authorised treatment for COVID-19. Whereas there are 5 trials involving NK cell for investigations (Lythgoe, & Middleton, 2020) , compare to the above treatment strategies, it is relatively far away to be developed as an intervention strategy in COVID- 19 . Lastly, ivermectin is still under investigation with a pending clinical trial, potential role in COVID-19 must be fully confirmed before deployment of global use (Table 1) . Further clinical trials are expected to be conducted to obtain high-quality data for assessing potentials therapies objectively, so as to assure its effectiveness is satisfactory for COVID-19 qualified therapy. It is believed that there are more international collaboration and the globalisation of clinical trials with larger sample size which have a reliable scientific rationale and statistical rigour for providing conclusive results.

By and large, many clinical trials are focusing on antiviral treatments with certain amounts of them targeting in antimalarial drugs, this stands for some point of view that repositioning and repurposing the existing drugs are the main trends in the future therapeutic strategies. The repurposed drugs raise considerable interest in being the optimal therapeutic option in managing CoV infections, owing to their advantage of easy availability, known pharmacokinetic properties, sides effects and also well-established regimens (Pillaiyar, Meenakshisundaram, & Manickam, 2020) . It is forecasted that developmental antiviral treatments would be the fastest approved therapeutic intervention for COVID-19, efforts should also be directed toward evaluating immunotherapies and cellular therapies that are effective against viruses similar to SARS-CoV-2. 

The recent COVID-19 outbreak has been deemed a global misfortune, especially the COVID-19 cases on the Diamond Princess Cruise Ship, which have raised ethical consideration concerning the psychological fragility and quality of life of the isolated passengers and crew members (Nakazawa, Ino, & Akabayashi, 2020). Apart from feeling their desperation and fear for tomorrow etched in the worried lines of their face, it is realized that the spread of COVID-19 cannot be fully restricted by quarantine alone. Such pathogenic COVID-19 is, therefore, demanding efficient therapeutic interventions to precisely treat the sufferers and prevent the new spread. Although there are no specific therapies approved by the FDA for COVID-19, many potential therapies are now under development given the similarities and epidemiological characteristics of SARS-CoV. It has been confirmed that SARS-CoV-2 is genetically similar to SARS-CoV and share the same receptor ACE2. Cytokine storm is also observed in all SARS-CoV-2, SARS-CoV and MERS-CoV infections, therefore several antiviral treatments for SARS-CoV and MERS-COV infection have been considered for the COVID-19 rescue. Among the various treatment methods, remdesivir is one of the most promising antiviral therapeutics by acting an inhibitor of RdRp to terminate viral RNA synthesis. While CQ and HCQ exert multiple mechanisms to inhibit the viral entry, viral receptor glycosylation, post-translational modification of the viral protein, couple with immunomodulating activities, reflecting they have robust therapeutic values of COVID-19 treatments with pharmaceutical drugs, in which a synergistic effect was demonstrated in the combination of HCQ and azithromycin. Ivermectin is an anti-parasitic drug which shows a potential antiviral ability against SARS-CoV-2 in vitro, its true inhibitory effect is yet to be determined. Besides, the neutralizing effect of antibodies is shown in CP therapy to suppress viral load and improve the immune system, which heightens its value in immunotherapy for COVID-19. Likewise, superior effector functions in NK cell therapy to enhance immunity also features its possible role in cellular therapy for COVID-19 pneumonia. While urgent, the impact of patient-derived mutation should be taken into account to prevent unexpected risk. Nevertheless, the present review is limited by the non-stopping changing of the COVID-19, ever-updating statistics and the continued unravelling of new study findings. Although researches are in progress to evaluate the clinical impacts of each therapy, the documented clinical data on different treatment approaches for SARS-CoV-2 are under demand.

Undoubtedly, the novel COVID-19 pandemic is one of the biggest humanity challenges. The near and distant future is accumulated by all those irreplaceable days. Lessons from the 2003 SARS outbreak have already warned us not to exclude the possibility of new outbreaks of SARS (Savarino et al., 2003) . There is no time for us to sacrifice the lives of today; instead, it is now the time for us to demand a concerted endeavor for COVID-19 rescue. Further research should be conducted to define the exact mechanism of SARS-CoV-2 pathogenesis, suitable animal models or ex vivo human lung tissues aid in studying replication, transmission and spread of the novel viruses, thereby facilitating the development of the therapeutic intervention. Also, clinical trials should be focused on the determinants of therapies safety and efficacy.

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

Natural Killer Cell Therapy: A Look Inside a 'Living Drug in a Bottle

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol

Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia

Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors

Need to test Azithromycin as first-line therapy for Covid-19

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet infectious diseases

Ocular onchocerciasis: current management and future prospects

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Early Report on Remdesivir: Is There a Benefit for Severe COVID-19?

Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill

Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities

Pharmacology of chloroquine and hydroxychloroquine

Time to use the p-word? Coronavirus enter dangerous new phase

The FDAapproved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

Use of ivermectin in dogs and cats

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Disappearance of antibodies to SARS-associated coronavirus after recovery

The convalescent sera option for containing COVID-19

Coronavirus Disease 2019 cases in the US

Frequently Asked Questions on Coronavirus Disease 2019 (COVID-19)

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Convalescent plasma as a potential therapy for COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Use of convalescent plasma therapy in SARS patients in Hong Kong

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

The Vietnam Chloroquine Treatment on COVID-19 (VICO)

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies

Clinical trial registration: a statement from the International Committee of Medical Journal Editors

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Reduction and functional exhaustion of T cells in patients

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study

Clinical pharmacokinetics and metabolism of chloroquine

Coronaviruses: an overview of their replication and pathogenesis

Convalescent Plasma Therapy for Covid-19: State of the Art

A case of fatal hydroxychloroquine overdose

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection

Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission

Compassionate Use of Remdesivir for Patients with Severe Covid-19

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Chloroquine: is a 70-year-old treatment for malaria the key to beating coronavirus? The Telegraph

Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Antibodies for Infectious Diseases

Natural killer cell specificity for viral infections

Hepatitis E virus in blood components: a prevalence and transmission study in southeast England

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

First case of 2019 novel coronavirus in the United States

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

An interferon-γ-related cytokine storm in SARS patients

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Azithromycin shows anti-Zika virus activity in human glial cells

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience

Successful treatment of avian influenza with convalescent plasma

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK

Up on the tightrope: natural killer cell activation and inhibition

Antibody-dependent cellular cytotoxity mediated by plasma obtained before secondary dengue virus infections: Potential involvement in early control of viral replication

A major outbreak of severe acute respiratory syndrome in Hong Kong

Here today-not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections

Molecular immune pathogenesis and diagnosis of COVID-19

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment

Research as a part of public health emergency response

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

Evaluation of Ebola virus inhibitors for drug repurposing

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

February) Gilead's remdesivir enters China phase III trial to fight coronavirus

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. The American journal of medicine

Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view

Role of interleukin-12 in primary influenza virus infection

Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease

Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus

Chronology of COVID-19 cases on the Diamond Princess cruise ship and ethical considerations: a report from Japan

Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics

The role of IL-12, IL-23 and IFN-γ in immunity to viruses

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections

Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control

Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?

The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy

Coronaviruses post-SARS: update on replication and pathogenesis

Recent discovery and development of inhibitors targeting coronaviruses

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells

Intracellular localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein: absence of nucleolar accumulation during infection and after expression as a recombinant protein in Vero cells

Evaluation of convalescent whole blood for treating Ebola Virus Disease in

Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet infectious diseases

Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells

Interferon-γ: an overview of signals, mechanisms and functions

Will an old malaria drug help fight the coronavirus? France 24

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan

Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

Activation of NK cell cytotoxicity

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

The intracellular sites of early replication and budding of SARS-coronavirus

A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae)

Rajeev Venkayya, President, Global Vaccine Business Unit on the latest on the Coronavirus and Takeda

Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells

protection against all 4 DENV serotypes by the inhibitor Ivermectin

COVID-19 Drug Therapy -Potential Options

Structural insights into coronavirus entry

Gates Foundation Funded French Research Group Commences Ivermectin Clinical Trial Targeting COVID-19

COVID-19 and Italy: what next

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Unexpected receptor functional mimicry elucidates activation of coronavirus fusion

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

NK cellmediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

Kamada to attempt coronavirus treatment

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

COVID-19 Coronavirus Pandemic

Coronavirus disease 2019 (COVID-19): situation report

Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services

WHO Director-General's opening remarks at the media briefing on COVID-19 -3

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine

The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer

Patient-derived mutations impact pathogenicity of SARS-CoV-2

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

A serological survey on neutralizing antibody titer of SARS convalescent sera

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Natural Killer Cell (CYNK-001) Infusions in Adults With

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

The work was partially supported by grants from The Science Technology and Innovation Commit-